This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Adam Feuerstein's Biotech Blog

Adam Feuerstein's Biotech Blog

Adam Feuerstein

Adam Feuerstein investigates the highly-speculative world of biotech stocks, and helps biotech investors avoid losing money.

To participate in Adam's "Biotech Stock Mailbag," please send your questions or comments using this form.

To chat with Adam on Twitter, click here.

Biotech Blog

Advancing the new Vertex drugs into the clinic should also quiet, but not eliminate, investor concerns about competitors closing the gap on the company's market-dominant position in cystic fibrosis treatments.
10/8/15 12:10PM
Biogen has the opportunity to make amends for its second-quarter earnings blow-up when it reports third-quarter earnings in two weeks.
10/8/15 8:49AM
The FDA placed a halt on clinical trials involving a cancer immunotherapy from Advaxis because of concerns a bacteria used to deliver the drug contributed to a patient death.
10/6/15 5:07PM
An independent panel of health care experts did not include Exact Sciences' Cologuard on a draft list of recommended colon cancer screening tests in the U.S.
10/6/15 10:44AM
Using cash to settle the debt was MannKind's worst-case option because it leaves the company with little money to fund ongoing operations.
10/5/15 12:53PM
There's a valuable, albeit painful, lesson here in Amicus' blow-up. Biotech CEOs should shut their mouths about regulatory plans until they receive definitive word from the FDA.
10/2/15 10:43AM
Biotech columnist Adam Feuerstein answers readers' questions about health care.
10/2/15 6:09AM
Sarepta hopes the new data will convince FDA to approve eteplirsen as a new treatment for Duchenne early next year.
10/1/15 7:05AM
The bloodletting in biotech stocks continued Monday with aggressive selling erasing the year's gains in a key sector exchange-traded fund. Another closely followed ETF is barely hanging on to outperformance.
9/28/15 1:33PM
Bristol's Opdivo is likely to be used ahead of Exelixis' Cometriq to treat advanced kidney cancer patients, doctor says.
9/25/15 6:02PM
Biotech columnist Adam Feuerstein answers readers' questions about health care.
9/25/15 7:05AM
If Clinton's proposal is implemented, biotech companies would have less time to generate profits from their expensive biologic drugs before other companies could enter the market with cheaper copies.
9/22/15 7:31AM
The major biotech stock indices fell Monday minutes after Democratic presidential candidate Hillary Clinton tweeted that she'll release a plan to tackle escalating drug prices on Tuesday.
9/21/15 12:50PM
Biotech columnist Adam Feuerstein answers readers' questions about health care.
9/18/15 6:11AM
Slightly more than 300 out of a required 348 brain tumor patients are currently enrolled in Northwest Bio's DCVax-L phase III study.
9/16/15 2:24PM
Schizophrenia patients treated with an experimental drug from Intra-Cellular Therapies reported fewer antipsychotic symptoms compared to a placebo in a large, phase III study, the company said Wednesday.
9/16/15 11:10AM
Amgen is acquiring a privately held company developing a cholesterol-lowering pill just weeks after receiving approval for its own cholesterol-lowering injection.
9/16/15 9:47AM
An experimental pill from Xenoport reduced psoriasis skin symptoms significantly more than a placebo in a mid-stage study, but a high rate of diarrhea raises questions about the drug's future.
9/15/15 9:59AM
A Tetraphase insider executed a well-timed insider stock sale right before the company's share price fell on negative clinical trial results.
9/14/15 6:27AM
FDA missed a deadline earlier this week to finalize the Biomarin/Sarepta advisory panels on Nov. 23-24, if (and only if) Nov. 23-24 were the chosen dates.
9/10/15 11:39AM
Spark Therapeutics provided details Thursday about changes made to a clinical trial involving the company's gene therapy, trying to calm jittery biotech investors before study results next month.
9/10/15 11:00AM
Biogen stepped into the oral S1P modulator race Wednesday with the acquisition of a license to develop a mid-stage compound from Japan's Mitsubishi Tanabe Pharma.
9/9/15 9:24AM
The Santhera drug, Raxone, is the first approved treatment for Leber hereditary optic neuropathy (LHON), which affects approximately 10,000 patients in Europe.
9/9/15 1:01AM
Four biotech companies announced important clinical trials results Tuesday at market close.
9/8/15 4:41PM

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Real Money
Try it NOW

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums


Chart of I:DJI
DOW 17,084.49 +33.74 0.20%
S&P 500 2,013.43 +15.91 0.80%
NASDAQ 4,830.47 +19.6820 0.41%
Top Rated Stocks Top Rated Funds Top Rated ETFs